Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.46 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3035936 | 0.84 | PTGS2 (0.47) | PTGS2CHRNA7PTGER1ALDH1A1MAPT | |
| SCHEMBL3019784 | 0.82 | PTGS2 (0.56) | PTGS2ALDH1A1MAPTPKMHTT | |
| SCHEMBL3024752 | 0.79 | MEN1 (0.52) | PTGS2CHRNA7ALDH1A1MAPTPKM | |
| SCHEMBL3032176 | 0.77 | PTGS2 (0.73) | PTGS2 | |
| SCHEMBL3024630 | 0.72 | PTGS2 (0.57) | PTGS2CHRNA7PTGER1ALDH1A1MAPT | |
| SCHEMBL3026195 | 0.71 | PTGS2 (0.52) | PTGS2ALDH1A1MAPTPKMHTT | |
| SCHEMBL3026333 | 0.70 | PTGS2 (0.78) | PTGS2PTGER1ALDH1A1MAPTKDM4E | |
| SCHEMBL7215254 | 0.70 | PTGS2 (0.78) | PTGS2PTGER1ALDH1A1MAPTKDM4E | |
| SCHEMBL3035294 | 0.69 | PTGS2 (0.88) | PTGS2PTGER1ALDH1A1MAPTPKM | |
| SCHEMBL811119 | 0.69 | HTR2A (0.55) | ALDH1A1MAPTHTTKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609713-B2 | Pyrrole derivatives and their methods of use | ABBVIE INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-20100216748-A1 | Pyrrole Derivatives and Their Methods of Use | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | disclosed |
| US-7741364-B2 | Neuronal nicotinic acetylcholine receptor modulators; such as ethyl 1-[4-(aminosulfonyl)phenyl]-5-(4-bromophenyl)-2-methyl-1H-pyrrole-3-carboxylate | ABBOTT LABORATORIES (US) | 2010-06-22 | — | — | US | disclosed |
| US-20080064695-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | ABBVIE INC. | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064695-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | PYCR1, PPOX, DHPS | PTGS2 69/4885CHRNA7 4801/4885PTGER1 168/4885 |
| US-20100216748-A1 | Pyrrole Derivatives and Their Methods of Use | PYCR1, PPOX, DHPS | PTGS2 69/4885CHRNA7 4801/4885PTGER1 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.